Prophylaxis of spontaneously developing mammary carcinoma in C3H-HeJ female mice by suppression of prolactin

Published on Thursday, 31 October 2019


Daily treatment for 1 year of young nulliparous C3H/HeJ mice with 2-bromo-α-ergocryptine (CB-154), an efficacious inhibitor of prolactin secretion, markedly suppressed mammary hyperplastic alveolar nodular development and virtually eliminated the appearance of mammary tumors.

Mature multiparous C3H/HeJ mice treated similarly also had reduced numbers of hyperplastic alveolar nodules and decreased mammary tumor incidence, but the response to the ergot was not as striking as that observed in the younger nulliparous mice. 2-Bromo-α-ergocryptine treatment was, however, generally ineffective in promoting regression of palpable mammary tumors in mature multiparous C3H/HeJ mice. Treatment with 2-bromo-α-ergocryptine had no significant effect on pituitary, ovarian, uterine, adrenal, or body weight, nor did it alter the estrous cycles.

The results of this study suggest that prolactin is an important, perhaps essential, hormone in the developmental phases of mouse mammary tumorigenesis. However, this hormone is of considerably less importance in the more advanced stages of the disease.

Upon the establishment of the hormone as a prerequisite for the development of human breast cancers, the use of appropriate drug-mediated hormone suppression as a prophylactic treatment for the disease may become feasible.


About this publication.

See also:

- Official Web Site: The Di Bella Method;

- The Di Bella Method (A Fixed Part - Bromocriptine and/or Cabergoline);

- The Di Bella Method (A Fixed Part - Cyclophosphamide 50mg tablets and/or Hydroxyurea 500mg tablets, one or two per day);

- The Di Bella Method (A Fixed Part - Somatostatin, Octreotide, Sandostatin LAR, analogues and/or derivatives);

- Somatostatin in oncology, the overlooked evidences - In vitro, review and in vivo publications;

- Publication: Over-Expression of GH/GHR in Breast Cancer and Oncosuppressor Role of Somatostatin as a Physiological Inhibitor (from Di Bella's Foundation);

- Publication: The over-expression of GH/GHR in tumour tissues with respect to healthy ones confirms its oncogenic role and the consequent oncosuppressor role of its physiological inhibitor, somatostatin: a review of the literature (from Di Bella's Foundation);

- Publication: The Entrapment of Somatostatin in a Lipid Formulation: Retarded Release and Free Radical Reactivity (from Di Bella's Foundation);

- The Di Bella Method (A Fixed Part - Melatonin tablets. From 30-40mg/day up to 200mg/day orally in patients with advanced stage of cancer disease and/or patients without respond to traditional treatments);

- Melatonin with adenosine solubilized in water and stabilized with glycine for oncological treatment - technical preparation, effectivity and clinical findings;

- About Melatonin - In vitro, review and in vivo publications;

- Publication: Melatonin anticancer effects: Review (from Di Bella's Foundation);

- Publication: Key aspects of melatonin physiology: 30 years of research (from Di Bella's Foundation);

- The Synergism of Somatostatin, Melatonin, Vitamins Prolactin and Estrogen Inhibitors Increased Survival, Objective Response and Performance Status In 297 Cases of Breast Cancer;

- Complete objective response, stable for 5 years, with the Di Bella Method, of multiple-metastatic carcinoma of the breast;

- Evaluation of the safety and efficacy of the first-line treatment with somatostatin combined with melatonin, retinoids, vitamin D3, and low doses of cyclophosphamide in 20 cases of breast cancer: a preliminary report;

- The Di Bella Method (DBM) improved survival, objective response and performance status in a retrospective observational clinical study on 122 cases of breast cancer;

- Complete objective response to biological therapy of plurifocal breast carcinoma;

- Recurrent Glioblastoma Multiforme (grade IV – WHO 2007): a case of complete objective response achieved by means of the concomitant administration of Somatostatin and Octreotide – Retinoids – Vitamin E – Vitamin D3 – Vitamin C – Melatonin – D2 R agonists (Di Bella Method – DBM) associated with Temozolomide;

- The Di Bella Method DBM improved survival objective response and performance status in a retrospective observational clinical study on 23 tumours of the head and neck;

- Neuroblastoma: Complete objective response to biological treatment;

- Oesophageal squamocellular carcinoma: a complete and objective response.